Search

Your search keyword '"Untucht, Robert"' showing total 13 results
Start Over Author "Untucht, Robert"
13 results on '"Untucht, Robert"'

1. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

Author

Kiernan, Matthew, Mathers, Susan, Henderson, Robert, Needham, Merrilee, Schultz, David, Löscher, Wolfgang, Mitrovic, Nenad, Rath, Jakob, Damme, Philip Van, De Bleecker, Jan L., Delstanche, Stéphanie, Johnston, Wendy, Zinman, Lorne, O'Connell, Colleen, Matte, Genevieve, Dionne, Annie, Korngut, Lawrence, Turnbull, John, Laaksovirta, Hannu, Jokela, Manu, Tapiola, Tero, Soriani, Marie-Hélène, Couratier, Philippe, Camu, William, Corcia, Philippe, Ludolph, Albert, Großkreutz, Julian, Meyer, Thomas, Boentert, Matthias, Schrank, Berthold, Prudlo, Johannes, Untucht, Robert, Hardiman, Orla, Siciliano, Gabriele, Chio', Adriano, Mazzini, Letizia, Inghilleri, Maurizio, Caponnetto, Claudia, Mora, Gabriele, Mora Pardina, Jesús S, Farrero Munoz, Eva, Vázquez Costa, Juan F, Aguera Morales, Eduardo, Varona, Luis, Andersen, Peter, Ingre, Caroline, Johansson, Rune, Radunovic, Aleksandar, Young, Carolyn, Babu, Suma, Shaibani, Aziz, Staff, Nathan, Vu, Tuan, Rivner, Michael, Scelsa, Stephen, Sivakumar, Kumaraswamy, Waheed, Waqar, Heitzman, Daragh, Rana, Sandeep, Pattee, Gary, Ajroud-Driss, Senda, Bayat, Elham, Kasarskis, Edward, Lange, Dale J, Elliott, Michael, Harris, Brent, Felice, Kevin, Pulley, Michael T, Kwan, Justin, Brown, Martin, Ravits, John, Burford, Matthew, Karam, Chafic, Miller, Timothy, Andrews, Jinsy, Levine, Todd, Locatelli, Eduardo, Wymer, James, Bedlack, Richard, Fee, Dominic, Goyal, Namita, Oskarsson, Bjorn, McCluskey, Leo, Caress, James, Weiss, Michael, Quick, Adam, Bromberg, Mark, Lacomis, David, Goutman, Stephen, Rezania, Kourosh, Guliani, Gaurav, Goslin, Kimberly, Katz, Jonathan S, Cudkowicz, Merit, Genge, Angela, Maragakis, Nicholas, Petri, Susanne, van den Berg, Leonard, Aho, Valtteri V, Sarapohja, Toni, Kuoppamäki, Mikko, Garratt, Chris, and Al-Chalabi, Ammar

Published
2021
Full Text
View/download PDF

4. Successful treatment of an adult with symptomatic attention deficit, hyperactivity, and impulsivity after temporal lobe resection: case report

Author

Untucht, Robert and Reif, Andreas

Abstract

Attention deficit hyperactivity disorder (ADHD) is defined by inattentiveness, impulsivity, and/or hyperactivity and mandatorily requires an onset in childhood. Structural or functional anatomical abnormalities have mostly been found in the prefrontal cortex, the corpus callosum, the striatum, and the cerebellum. We here present the case of an adult woman who developed severe symptoms analogous to ADHD after right temporal lobectomy. Surgery had been necessary because of a large temporobasal arterio-venous malformation (AVM). The patient’s childhood and personal history before surgery had been without any indication of ADHD or any other mental disorder. Because of her distinct and impairing symptoms of ADHD, we initiated off-label methylphenidate treatment, achieving strong reduction in the symptoms. This proves further similarity of her symptomatic disorder to ADHD and supports a role of the right temporal lobe in ADHD.

Published
2024
Full Text
View/download PDF

5. The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies

Author

Raeder, Vanessa, primary, Batzu, Lucia, additional, Untucht, Robert, additional, Fehre, Annekathrin, additional, Rizos, Alexandra, additional, Leta, Valentina, additional, Schmelz, Renate, additional, Hampe, Jochen, additional, Bostantjopoulou, Sevasti, additional, Katsarou, Zoe, additional, Storch, Alexander, additional, Reichmann, Heinz, additional, Falkenburger, Björn, additional, Ray Chaudhuri, K., additional, and Klingelhoefer, Lisa, additional

Published
2023
Full Text
View/download PDF

8. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

Author

Cudkowicz, Merit, primary, Genge, Angela, additional, Maragakis, Nicholas, additional, Petri, Susanne, additional, van den Berg, Leonard, additional, Aho, Valtteri V, additional, Sarapohja, Toni, additional, Kuoppamäki, Mikko, additional, Garratt, Chris, additional, Al-Chalabi, Ammar, additional, Kiernan, Matthew, additional, Mathers, Susan, additional, Henderson, Robert, additional, Needham, Merrilee, additional, Schultz, David, additional, Löscher, Wolfgang, additional, Mitrovic, Nenad, additional, Rath, Jakob, additional, Damme, Philip Van, additional, De Bleecker, Jan L., additional, Delstanche, Stéphanie, additional, Johnston, Wendy, additional, Zinman, Lorne, additional, O'Connell, Colleen, additional, Matte, Genevieve, additional, Dionne, Annie, additional, Korngut, Lawrence, additional, Turnbull, John, additional, Laaksovirta, Hannu, additional, Jokela, Manu, additional, Tapiola, Tero, additional, Soriani, Marie-Hélène, additional, Couratier, Philippe, additional, Camu, William, additional, Corcia, Philippe, additional, Ludolph, Albert, additional, Großkreutz, Julian, additional, Meyer, Thomas, additional, Boentert, Matthias, additional, Schrank, Berthold, additional, Prudlo, Johannes, additional, Untucht, Robert, additional, Hardiman, Orla, additional, Siciliano, Gabriele, additional, Chio', Adriano, additional, Mazzini, Letizia, additional, Inghilleri, Maurizio, additional, Caponnetto, Claudia, additional, Mora, Gabriele, additional, Mora Pardina, Jesús S, additional, Farrero Munoz, Eva, additional, Vázquez Costa, Juan F, additional, Aguera Morales, Eduardo, additional, Varona, Luis, additional, Andersen, Peter, additional, Ingre, Caroline, additional, Johansson, Rune, additional, Radunovic, Aleksandar, additional, Young, Carolyn, additional, Babu, Suma, additional, Shaibani, Aziz, additional, Staff, Nathan, additional, Vu, Tuan, additional, Rivner, Michael, additional, Scelsa, Stephen, additional, Sivakumar, Kumaraswamy, additional, Waheed, Waqar, additional, Heitzman, Daragh, additional, Rana, Sandeep, additional, Pattee, Gary, additional, Ajroud-Driss, Senda, additional, Bayat, Elham, additional, Kasarskis, Edward, additional, Lange, Dale J, additional, Elliott, Michael, additional, Harris, Brent, additional, Felice, Kevin, additional, Pulley, Michael T, additional, Kwan, Justin, additional, Brown, Martin, additional, Ravits, John, additional, Burford, Matthew, additional, Karam, Chafic, additional, Miller, Timothy, additional, Andrews, Jinsy, additional, Levine, Todd, additional, Locatelli, Eduardo, additional, Wymer, James, additional, Bedlack, Richard, additional, Fee, Dominic, additional, Goyal, Namita, additional, Oskarsson, Bjorn, additional, McCluskey, Leo, additional, Caress, James, additional, Weiss, Michael, additional, Quick, Adam, additional, Bromberg, Mark, additional, Lacomis, David, additional, Goutman, Stephen, additional, Rezania, Kourosh, additional, Guliani, Gaurav, additional, Goslin, Kimberly, additional, and Katz, Jonathan S, additional

Published
2021
Full Text
View/download PDF

10. Validation of a self‐completed Dystonia Non‐Motor Symptoms Questionnaire

Author

Klingelhoefer, Lisa, primary, Chaudhuri, Kallol R., additional, Kamm, Christoph, additional, Martinez‐Martin, Pablo, additional, Bhatia, Kailash, additional, Sauerbier, Anna, additional, Kaiser, Maximilian, additional, Rodriguez‐Blazquez, Carmen, additional, Balint, Bettina, additional, Untucht, Robert, additional, Hall, Lynsey J., additional, Mildenstein, Lauritz, additional, Wienecke, Miriam, additional, Martino, Davide, additional, Gregor, Olaf, additional, Storch, Alexander, additional, and Reichmann, Heinz, additional

Published
2019
Full Text
View/download PDF

12. Designing and cloning of a targeting vector for generating plasma kallikrein deficient mice

Author

Untucht, Robert

Subjects
ddc:610, Maus, Kallikreine
Abstract

Gegenstand dieser Arbeit ist die Erstellung eines sogenannten "Targeting Vektors" zur gezielten Ausschaltung des Gens für Plasmakallikrein in der Maus, als Vorbereitung zur Schaffung einer Plasmakallikrein-defizienten Mauslinie. Plasmakallikrein ist eine im Blut zirkulierende Serinprotease, die Funktionen in Hämostase, Thrombusbildung und Fibrinolyse hat sowie sowohl direkt als auch indirekt mittels Bradykinin an Entzündungsvorgängen beteiligt ist. Zwei 5836 und 3834 bp lange Abschnitte aus dem murinen Plasmakallikrein-Gen wurden durch PCR isoliert und in ein Plasmid kloniert, das neben Resistenzgenen gegen Ampicillin und Neomycin auch das β-Galaktosidase-Gen zum Nachweis einer erfolgreichen Transfektion enthält. Der so entstandene "Targeting Vektor" hat eine Gesamtgröße von 18072 bp, die Basensequenz wurde durch Sequenzierung verifiziert. Der Vektor soll im Plasmakallikrein-Gen einen Teil der Exons 2 und 3 und damit einen Großteil des Signalpeptids und der ersten Proteindomäne funktionsunfähig machen. An den mit dieser Methode erstellten Knockout-Mäusen können die Funktionen von Plasmakallikrein genauer untersucht werden., This thesis describes the cloning of a targeting vector in the gene targeting strategy for a murine plasma kallikrein (PK) knock-out. PK is a serine protease found in blood which has functions in hemostasis, thrombus formation, fibrinolysis and – both directly and indirectly via bradykinin – inflammation. Two fragments of the murine PK gene with respective lengths of 5836 and 3834 bp were isolated by PCR and cloned into a plasmid containing resistance genes against both ampicillin and neomycin and the β-galactosidase gene for the detection of transfected cells. The targeting vector has a total size of 18072 bp and was verified by sequencing. The vector should destroy parts of the exons 2 and 3 in the gene for PK and thus the greater part of the signal peptide and the first protein domain. With the knock-out mice created by this means the function of PK can be investigated more thoroughly.

Published
2012

13. Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol

Author

Albanese Alberto, Ludolph, Albert Christian, McDermott, Christopher J, Corcia, Philippe, Van Damme, Philip, Van den Berg, Leonard H, Hardiman, Orla, Rinaldi, Gilberto, Vanacore, Nicola, Dickie, Brian, TUDCA-ALS Study Group, Paolo Tornese, Antoniangela Cocco, Maria Lo Giudice, Michela Matteoli, Eliana Lauranzano, Maria Luisa Malosio, Chiara Adriana Elia, Flavia Lombardo, Flavia Mayer, Maria Puopolo, Stefania Spila Alegiani, Adriano Chiò, Umberto Manera, Cristina Moglia, Andrea Calvo, Paolina Salamone, Giuseppe Fuda, Carlo Colosimo, Cristina Spera, Prabha Cristina Ranchicchio, Giuseppe Stipa, Domenico Frondizi, Christian Lunetta, Valeria Sansone, Claudia Tarlarini, Francesca Gerardi, Vincenzo Silani, Alberto Doretti, Eleonora Colombo, Gianluca Demirtzidis, Gioacchino Tedeschi, Francesca Trojsi, Carla Passaniti, Stefania Ballestrero, Johannes Dorst, Ulrike Weiland, Andrea Fromm, Maximilian Wiesenfarth, Katharina Kandler, Simon Witzel, Markus Otto, Joachim Schuster, Thomas Meyer, André Maier, Dagmar Kettemann, Susanne Petri, Lars Müschen, Camilla Wohnrade, Anastasia Sarikidi, Alma Osmanovic, Julian Grosskreutz, Annekathrin Rödiger, Robert Steinbach, Benjamin Ilse, Uta Smesny, Robert Untucht, René Günther, Maximilian Vidovic, Pamela Shaw, Alexis Collins, Helen Wollff, Theresa Walsh, Lee Tuddenham, Mbombe Kazoka, David White, Stacy Young, Benjamin Thompson, Daniel Madarshahian, Suresh K Chhetri, Amina Chaouch, Carolyn A Young, Heike Arndt, Oliver C Hanemann, Thomas Lambert, Stephane Beltran, Philippe Couratier, Florence Esselin, William Camu, Elisa De, La Cruz, Gwendal Lemasson, Pegah Masrori, Sinead Maguire, Liz Fogarty, Toyosi Atoyebi, Niamh Ní Obáin, Tornese, Paolo, Cocco, Antoniangela, Giudice, Maria Lo, Matteoli, Michela, Lauranzano, Eliana, Malosio, Maria Luisa, Adriana Elia, Chiara, Lombardo, Flavia, Mayer, Flavia, Puopolo, Maria, Alegiani, Stefania Spila, Chiò, Adriano, Manera, Umberto, Moglia, Cristina, Calvo, Andrea, Salamone, Paolina, Fuda, Giuseppe, Colosimo, Carlo, Spera, Cristina, Ranchicchio, Prabha Cristina, Stipa, Giuseppe, Frondizi, Domenico, Lunetta, Christian, Sansone, Valeria, Tarlarini, Claudia, Gerardi, Francesca, Silani, Vincenzo, Doretti, Alberto, Colombo, Eleonora, Demirtzidis, Gianluca, Tedeschi, Gioacchino, Trojsi, Francesca, Passaniti, Carla, Ballestrero, Stefania, Dorst, Johannes, Weiland, Ulrike, Fromm, Andrea, Wiesenfarth, Maximilian, Kandler, Katharina, Witzel, Simon, Otto, Markus, Schuster, Joachim, Meyer, Thomas, Maier, André, Kettemann, Dagmar, Petri, Susanne, Müschen, Lars, Wohnrade, Camilla, Sarikidi, Anastasia, Osmanovic, Alma, Grosskreutz, Julian, Rödiger, Annekathrin, Steinbach, Robert, Ilse, Benjamin, Smesny, Uta, Untucht, Robert, Günther, René, Vidovic, Maximilian, Shaw, Pamela, Collins, Alexis, Wollff, Helen, Walsh, Theresa, Tuddenham, Lee, Kazoka, Mbombe, White, David, Young, Stacy, Thompson, Benjamin, Madarshahian, Daniel, Chhetri, Suresh K, Chaouch, Amina, Young, Carolyn A, Arndt, Heike, Hanemann, Oliver C, Lambert, Thomas, Beltran, Stephane, Couratier, Philippe, Esselin, Florence, Camu, William, De, Elisa, Cruz, La, Lemasson, Gwendal, Masrori, Pegah, Maguire, Sinead, Fogarty, Liz, Atoyebi, Toyosi, Obáin, Niamh Ní, Alberto, Albanese, Albert Christian, Ludolph, Christopher J, Mcdermott, Philippe, Corcia, Philip, Van Damme, Leonard H, Van den Berg, Orla, Hardiman, Gilberto, Rinaldi, Nicola, Vanacore, Brian, Dickie, Study Group, TUDCA-ALS, Lo Giudice, Maria, Luisa Malosio, Maria, Spila Alegiani, Stefania, Cristina Ranchicchio, Prabha, Dorst, Johanne, Otto, Marku, Meyer, Thoma, Müschen, Lar, Collins, Alexi, K Chhetri, Suresh, A Young, Carolyn, C Hanemann, Oliver, Lambert, Thoma, and Ní Obáin, Niamh

Subjects
bile acids, amyotrophic lateral sclerosis, therapy, Neurology, bile acid, clinical trial, phase III, amyotrophic lateral sclerosi, Neurology (clinical), ddc:610
Abstract

BackgroundAmyotrophic lateral sclerosis (ALS) is a chronic neurodegenerative rare disease that affects motor neurons in the brain, brainstem, and spinal cord, resulting in progressive weakness and atrophy of voluntary skeletal muscles. Although much has been achieved in understanding the disease pathogenesis, treatment options are limited, and in Europe, riluzole is the only approved drug. Recently, some other drugs showed minor effects.MethodsThe TUDCA-ALS trial is a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The study aims to enroll 320 patients in 25 centers across seven countries in Europe. Enrolled patients are randomized to one of two treatment arms: TUDCA or identical placebo by oral route. The study measures disease progression during the treatment period and compares it to natural progression during a no-treatment run-in phase. Clinical data and specific biomarkers are measured during the trial. The study is coordinated by a consortium composed of leading European ALS centers.ConclusionThis trial is aimed to determine whether TUDCA has a disease-modifying activity in ALS. Demonstration of TUDCA efficacy, combined with the validation of new biomarkers, could advance ALS patient care.Clinical trial registrationClinicalTrials.gov, identifier: NCT03800524.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results